1. Home
  2. HFBL vs KPTI Comparison

HFBL vs KPTI Comparison

Compare HFBL & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Home Federal Bancorp Inc. of Louisiana

HFBL

Home Federal Bancorp Inc. of Louisiana

HOLD

Current Price

$18.00

Market Cap

41.6M

Sector

Finance

ML Signal

HOLD

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$6.95

Market Cap

94.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HFBL
KPTI
Founded
1924
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.6M
94.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
HFBL
KPTI
Price
$18.00
$6.95
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$22.17
AVG Volume (30 Days)
2.9K
165.8K
Earning Date
01-29-2026
11-03-2025
Dividend Yield
2.98%
N/A
EPS Growth
35.20
N/A
EPS
1.47
N/A
Revenue
$21,720,000.00
$142,530,000.00
Revenue This Year
N/A
$3.82
Revenue Next Year
N/A
$3.18
P/E Ratio
$12.26
N/A
Revenue Growth
10.10
N/A
52 Week Low
$12.31
$3.51
52 Week High
$19.20
$12.45

Technical Indicators

Market Signals
Indicator
HFBL
KPTI
Relative Strength Index (RSI) 73.91 66.79
Support Level $15.90 $5.70
Resistance Level $19.20 $6.05
Average True Range (ATR) 0.29 0.45
MACD 0.19 0.16
Stochastic Oscillator 69.62 75.69

Price Performance

Historical Comparison
HFBL
KPTI

About HFBL Home Federal Bancorp Inc. of Louisiana

Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: